首页|口服阿奇霉素、口服及静脉红霉素治疗呼吸道支原体感染疗效及不良反应对比

口服阿奇霉素、口服及静脉红霉素治疗呼吸道支原体感染疗效及不良反应对比

扫码查看
目的 总结分析呼吸道支原体感染患者应用口服阿奇霉素、口服及静脉红霉素治疗的临床效果以及安全性.方法 以本院2014年4月~2016年9月期间接收的120例呼吸道支原体感染患者为研究对象,随机分为口服阿奇霉素组、口服红霉素组以及静脉红霉素组,各40例,回顾分析所有患者的临床治疗效果以及不良反应发生情况.结果 在治疗总有效率方面,口服阿奇霉素高于口服及静脉红霉素治疗方法,在不良反应发生率以及症状体征改善时间方面,口服阿奇霉素低于口服及静脉红霉素治疗方法,差异比较存在统计学意义(P<0.05).结论 对于呼吸道支原体感染采用口服阿奇霉素相对于口服及静脉红霉素治疗方法,效果更好,症状改善时间更短,安全性更高,值得临床推广应用.
Oral azithromycin,oral and intravenous erythromycin treatment of respiratory tract mycoplasma infection curative effect and adverse reaction of contrast
Objective To summarize analysis of respiratory tract mycoplasma infection in patients with oral azithromycin,oral and intravenous erythromycin treatment the clinical effect and safety.Methods From April 2014 to September 2016 received during the period of 120 patients with respiratory tract mycoplasma infection as the research object,were randomly divided into oral azithromycin, oral erythromycin group and intravenous erythromycin group,all patients were retrospectively analyzed the clinical therapeutic effects and adverse reactions occur.Results The total effective rate in treatment,oral azithromycin is higher than oral and intravenous treatment of erythromycin,Signs and symptoms in the incidence of adverse reactions and improve the time aspect,oral azithromycin is lower than the oral and intravenous treatment of erythromycin,diff there is statistical significance(P<0.05).Conclusion For respiratory tract mycoplasma infection adopt oral azithromycin compared with oral and intravenous erythromycin treatment,the effect is better,shorter symptom improvement,higher security,worthy of clinical popularization and application.

oral azithromycinoral erythromycinvenous erythromycinrespiratory tract mycoplasma infectionclinical curative effectadverse reactions

乐宇娜、顾剑烈

展开 >

宁波市北仑妇幼保健院 内科,浙江 宁波 315800

口服阿奇霉素 口服红霉素 静脉红霉素 呼吸道支原体感染 临床疗效 不良反应

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(7)
  • 2
  • 10